Compare EPR Properties (EPR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs BIO-TECHNE Corp — how do they compare? EPR Properties trades at $60 (market cap $4.63B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 2.4× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.16%). Which is the better fit depends on your goals.
| EPR | TECH | |
|---|---|---|
Market Cap | $4.63B | $11.24B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $72.29 |
52-Week Low | $48.71 | $43.31 |
Enterprise Value | $8.14B | $11.32B |
Dividend Yield | 6.16% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $62.20, up 1.4% today, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong profitability with a 91.41% gross margin and raised 2026 FFO guidance, supported by a new $1.6 billion credit facility announced on July 20, 2026. Key resistance is at $63, with support at $61.
Outlook is cautiously positive given analyst consensus of $65.30 price target and dividend stability, but risks include declining net income margins and high valuation multiples. Investment appeal hinges on execution of acquisition strategy amid economic sensitivity.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
